SCHEMBL440093

SCHEMBL440093

CCc1ccc2nc(N3CCN(C(=O)OC(C)(C)C)CC3)c3nncn3c2c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.59
HRH4 Q9H3N8 4/20 0.49
HRH3 Q9Y5N1 3/20 0.49
MAPT P10636 5/20 0.47
HPGD P15428 5/20 0.47
HSD17B10 Q99714 4/20 0.47
ALDH1A1 P00352 3/20 0.47
PKM P14618 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
TP53 P04637 4/20 0.46
KMT2A Q03164 3/20 0.46
MAPK1 P28482 2/20 0.46
HTT P42858 2/20 0.46
MEN1 O00255 1/20 0.46
LMNA P02545 1/20 0.46
CASP7 P55210 1/20 0.46
POLB P06746 2/20 0.46
ESR1 P03372 1/20 0.42
OPRM1 P35372 1/20 0.42
OPRD1 P41143 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL404380 0.87 KDM4E (0.56) KDM4EHRH4HRH3MAPTHPGD
SCHEMBL404405 0.87 HRH4 (0.66) KDM4EHRH4HRH3MAPTHPGD
SCHEMBL405963 0.85 KDM4E (0.55) KDM4EHRH4HRH3MAPTHPGD
SCHEMBL404402 0.81 KDM4E (0.50) KDM4EHRH4HRH3MAPTHPGD
SCHEMBL406016 0.81 HRH4 (0.73) KDM4EHRH4HRH3MAPTHPGD
SCHEMBL404397 0.80 KDM4E (0.51) KDM4EHRH4HRH3MAPTHPGD
SCHEMBL462720 0.80 KDM4E (0.49) KDM4EHRH4HRH3MAPTHPGD
SCHEMBL463615 0.79 KDM4E (0.48) KDM4EHRH4HRH3MAPTHPGD
SCHEMBL405654 0.78 HRH4 (0.56) KDM4EHRH4HRH3MAPTHPGD
SCHEMBL12225208 0.77 KDM4E (0.47) KDM4EHRH4HRH3MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120065187-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE ALCON RESEARCH, LTD (US) 2012-03-15 US disclosed
US-20110257137-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE KALYPSYS, INC. (US) 2011-10-20 US disclosed
WO-2011112731-A2 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE KALYPSYS, INC. (US) 2011-09-15 WO disclosed
EP-2324029-A2 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE Kalypsys, Inc. (US) 2011-05-25 EP disclosed
US-20100120741-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE KALYPSYS, INC. (US) 2010-05-13 US disclosed
WO-2010030785-A2 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE KALYPSYS INC. (US) 2010-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120741-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE HRH4, HRH3, HRH2 KDM4E 1897/4885HRH4 1/4885HRH3 2/4885
US-20120065187-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE HRH4, HRH3, HRH2 KDM4E 1897/4885HRH4 1/4885HRH3 2/4885
US-20110257137-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE HRH4, HRH3, HRH2 KDM4E 1897/4885HRH4 1/4885HRH3 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.